Tocilizumab treatment leads to improvement in disease activity regardless of CCP status in rheumatoid arthritis

Tocilizumab led to statistically significant improvement in all patient- and physician-reported measures of disease activity evaluated in this cohort of patient with RA. The response to tocilizumab did not differ by CCP status.